G-BA requested RWE collection for the second time – Fedratinib in myelofibrosis
Since 2020, the G-BA can request real-world evidence data collection in Germany. However, so far this was only implemented for one product,
Category: Orphan drugs
Regular and abbreviated early benefit assessments – Is this the end of orphan drug privileges?
This is the first article in a series about maybe the most important topic influencing market access in Germany: HTAs or early
G-BA assessment of CAR-T therapy Tecartus
The G-BA has now completed its benefit assessment of the CAR-T therapy, Tecartus, which is indicated for the treatment of mantle cell
Orphan drug re-assessments
What happens when the sales for an orphan drug exceed €50 mn in a 12 months period?